Plain-English translation of NCT04664946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called 3-n-butylphthalide to see if it can protect brain cells after a stroke. The medication is delivered directly into the blood vessels of the brain through a thin catheter (a small tube) rather than taken by mouth. This approach is being studied for patients who had a stroke but could not receive the standard emergency treatments that dissolve or remove blood clots.
Many stroke patients arrive at the hospital too late to receive emergency clot-removal treatments, or they have other conditions that prevent those treatments from being used. Researchers are testing whether this neuroprotective medication—delivered directly to the brain—can limit the damage caused by stroke in these patients who would otherwise have no treatment option.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo a procedure where doctors insert a thin catheter into an artery and guide it to your brain to deliver the medication directly to the affected area. The medication would be given continuously for 24 hours through this catheter. You would be monitored closely during this time to ensure safety, and the research team would follow your recovery to see how the treatment affects your stroke symptoms.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China
Sponsor
Hui-Sheng Chen
Enrollment target
~30 participants
Started
December 2020
Primary completion
May 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hui-Sheng T Chen, Ph.D.
Hui-Sheng Chen
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.